| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA1805453 |
| P698 | PubMed publication ID | 30134131 |
| P50 | author | Michael A Postow | Q87845565 |
| F Stephen Hodi | Q90321337 | ||
| P2093 | author name string | Anna C Pavlick | |
| Stergios J Moschos | |||
| Michael B Atkins | |||
| David A Reardon | |||
| Ahmad Tarhini | |||
| Omid Hamid | |||
| Peter A Forsyth | |||
| Kim Margolin | |||
| Igor Puzanov | |||
| Nikhil I Khushalani | |||
| Christopher D Lao | |||
| Marc S Ernstoff | |||
| Hussein A Tawbi | |||
| Alain Algazi | |||
| Karl Lewis | |||
| Ragini R Kudchadkar | |||
| Alexandre Avila | |||
| Reena P Thomas | |||
| Joel Jiang | |||
| Sheena Demelo | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 722-730 | |
| P577 | publication date | 2018-08-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain | |
| P478 | volume | 379 |
| Q92182771 | 5-year results for pembrolizumab treatment of advanced melanoma |
| Q89985469 | A case report: metastasis of melanoma to the heart in an era of immunotherapy |
| Q92563188 | Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases |
| Q90142120 | Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma |
| Q91646745 | Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma |
| Q92702383 | Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update |
| Q64084968 | Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma |
| Q97551455 | Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016 |
| Q94527313 | BRAF in malignant melanoma progression and metastasis: potentials and challenges |
| Q92652889 | Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies |
| Q64231724 | Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma |
| Q91736550 | Brain immunology and immunotherapy in brain tumours |
| Q91099817 | Brain metastases |
| Q99565896 | Brain metastases: lessons and challenges in the targeted therapy and immunotherapy era |
| Q91526515 | Brain metastasis |
| Q92245332 | CAR T cells for brain tumors: Lessons learned and road ahead |
| Q64277726 | CD271 is a molecular switch with divergent roles in melanoma and melanocyte development |
| Q100569692 | Changing Hands: A Rising Role of the Tumor Surgeon in Teaching Sylvian Fissure Dissection |
| Q89965015 | Clinical Value of Susceptibility Weighted Imaging of Brain Metastases |
| Q64267591 | Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma |
| Q89726549 | Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma |
| Q64910760 | Combination of CTLA-4 and PD-1 blockers for treatment of cancer. |
| Q90620509 | Combined Immunotherapy in Metastatic Melanoma with Unknown Primary |
| Q90711858 | Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients |
| Q90436833 | Complications associated with immunotherapy for brain metastases |
| Q91832432 | Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma |
| Q89672600 | Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases (BTIP-BM) |
| Q92457071 | Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma |
| Q89811416 | Current approaches to the management of brain metastases |
| Q92872909 | Current multidisciplinary management of brain metastases |
| Q90291777 | Current state of clinical trials in breast cancer brain metastases |
| Q89521108 | Do we have a "game changer" in treating patients with brain metastasis from renal cell carcinoma? |
| Q92261316 | Efficacy and safety of immune checkpoint blockade for brain metastases |
| Q97523107 | Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience |
| Q64095864 | Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial |
| Q97421387 | Evolving treatment strategies of brain metastases from breast cancer: current status and future direction |
| Q61811641 | Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy |
| Q90454353 | Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors |
| Q89767107 | Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas |
| Q91565220 | Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy |
| Q92684942 | How I treat metastatic melanoma |
| Q92640003 | Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma |
| Q57490955 | Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease |
| Q98386332 | Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy |
| Q89884047 | Immunotherapy for the Treatment of Breast Cancer: Emerging New Data |
| Q90291784 | Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries |
| Q89713650 | Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases |
| Q90410649 | Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases |
| Q64971042 | In vitro sensitivity of malignant melanoma cells lines to photon and heavy ion radiation. |
| Q92524861 | Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma |
| Q104617795 | Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes |
| Q64093580 | Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases |
| Q89965765 | Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment |
| Q96304658 | Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors |
| Q89690135 | Integration of immuno-oncology with stereotactic radiosurgery in the management of brain metastases |
| Q90971217 | Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series |
| Q64966271 | Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. |
| Q90445860 | Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response |
| Q89766256 | Intratumoral immunotherapy for early stage solid tumors |
| Q61799197 | L265P mutation and loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas |
| Q89840115 | Landscape of combination therapy trials in breast cancer brain metastasis |
| Q90811589 | Les métastases cérébrales de cancer du rein, un défi clinique |
| Q89987318 | Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure? |
| Q89521135 | Management of brain metastases from renal cell carcinoma |
| Q99406209 | Management of brain metastases: history and the present |
| Q64971747 | Management of metastatic cutaneous melanoma: updates in clinical practice. |
| Q98467275 | Medical management of brain metastases |
| Q98613187 | Melanoma brain metastases: review of histopathological features and immune-molecular aspects |
| Q92511346 | Microenvironmental Regulation of Tumor Progression and Therapeutic Response in Brain Metastasis |
| Q91759638 | Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases |
| Q90482809 | Molecular principles of metastasis: a hallmark of cancer revisited |
| Q98467276 | Multidisciplinary patient-centered management of brain metastases and future directions |
| Q91280474 | Neurologic complications of melanoma |
| Q89735158 | New survival standards for advanced melanoma |
| Q64939605 | Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date. |
| Q92226488 | Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature |
| Q92593427 | No paradigm changes with checkpoint inhibitor monotherapy in patients with metastatic renal cell carcinoma and brain metastases |
| Q89859375 | Not all cancers are created equal: Tissue specificity in cancer genes and pathways |
| Q90376945 | Operative and peri-operative considerations in the management of brain metastasis |
| Q96953882 | Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations |
| Q92293389 | Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy |
| Q92086166 | Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy) |
| Q92966111 | Phagocytosis checkpoints as new targets for cancer immunotherapy |
| Q89967055 | Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis |
| Q59808608 | Preoperative Stereotactic Radiosurgery for Brain Metastases |
| Q89669628 | Prognostic Biomarkers for Melanoma Immunotherapy |
| Q89599976 | Quoi de neuf en oncodermatologie ? |
| Q92200876 | Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study |
| Q59341081 | Recent advances in managing brain metastasis |
| Q99412933 | Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases |
| Q59795326 | Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma |
| Q93208698 | Severe radiation necrosis refractory to surgical resection in patients with melanoma and brain metastases managed with ipilimumab/nivolumab and brain-directed stereotactic radiation therapy |
| Q96127666 | Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis |
| Q99708289 | Stereotactic Radiosurgery After Resection of Brain Metastases: Changing Patterns of Care in the United States |
| Q91565714 | Stereotactic Radiosurgery to More Than 10 Brain Metastases: Evidence to Support the Role of Radiosurgery for Ideal Hippocampal Sparing in the Treatment of Multiple Brain Metastases |
| Q64055641 | Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity |
| Q91813691 | Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection |
| Q90481686 | Supportive roles of brain macrophages in CNS metastases and assessment of new approaches targeting their functions |
| Q89685712 | T lymphocyte-targeted immune checkpoint modulation in glioma |
| Q92061873 | Targeted Radiotherapy of the Tumor Cavity after Surgical Resection of Aggressive Recurrent Brain Metastasis: A Case Report |
| Q64067749 | Targeting Molecular Pathways in Intracranial Metastatic Disease |
| Q64055646 | The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation |
| Q90113096 | The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review |
| Q64950574 | The Potential of Astrocytes as Immune Modulators in Brain Tumors. |
| Q99402160 | The Role of Stereotactic Biopsy in Brain Metastases |
| Q92888273 | The Systemic Treatment of Melanoma |
| Q64987811 | The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018. |
| Q90474060 | The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q91740514 | The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis |
| Q89520966 | The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases |
| Q64981981 | The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis. |
| Q91649938 | Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis |
| Q90482925 | Trifluoperazine prolongs the survival of experimental brain metastases by STAT3-dependent lysosomal membrane permeabilization |
| Q64075498 | Turning "Cold" Into "Hot" Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers |
| Q91719589 | Two Decades of the Impact of Tasmanian Devil Facial Tumor Disease |
| Q89520814 | Unique behavior of brain metastases during the treatment of nivolumab for metastatic renal cell carcinoma |
| Q91843409 | Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control |
| Q94526286 | Use of immuno-oncology in melanoma |
| Q92669535 | VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours |
| Q91675179 | Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report |
| Q91336432 | What's new under the Sun for ICIs? |
| Q64946218 | Whole-brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma - final results of the BRAIN-RT trial. |
| Q58107626 | [Combination immunotherapy for patients with brain metastases of malignant melanoma: de-escalation only under controlled conditions with frequent imaging] |
| Q90743133 | [What's new in oncodermatology?] |
Search more.